Search

Your search keyword '"Jose, Vinu"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Jose, Vinu" Remove constraint Author: "Jose, Vinu"
46 results on '"Jose, Vinu"'

Search Results

2. Microtubule targeting agents influence the clinical benefit of immune response in early breast cancer.

Catalog

Books, media, physical & digital resources

3. Gene expression data from the FinHER adjuvant breast cancer trial comparing microtubule targeting agents

8. Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

11. Impact of treatments on the clinical value of immune response in breast cancer: an insilico analysis

12. Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial

13. Bevacizumab for eye diseases - Legal, regulatory, and ethical overview

18. Abstract 3853: The anti-tumor immune responses by active and quiescent tertiary lymphoid structures to breast cancer

19. FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer

23. FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer

24. Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays

25. Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus.

29. Changing trend in the use of antimicrobials over ten years in a tertiary care hospital

30. CD73 promotes resistance to HER2/ErbB2 antibody therapy

31. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.

32. Biology of breast cancer during pregnancy using genomic profiling.

33. Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.

34. Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

35. Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.

36. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC).

37. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC)

38. Effect of sample preservation method and transportation duration on tumor gene expression profiling in breast cancer.

39. Effect of sample preservation method and transportation duration on tumor gene expression profiling in breast cancer

42. Biology of breast cancer during pregnancy using genomic profiling.

43. Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients.

44. Changing chronobiology of cardiovascular outcome following prophylaxis.

45. Antiepileptic TDM pattern at a tertiary care hospital in India.

46. Effect of potassium channel modulators on toxicity of Cleistanthus collinus.